Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: David Howe who wrote (2173)	3/28/1999 6:19:00 PM
From: AJAG	Respond to of 10280

Over on the WLA discussion board, there is a reference to a Merrill Lynch Report that expresses the view that Celexa, the anti-depressant sold by Forest Labs and WLA, could take market share from Lilly's Prozac, due to a better side effect profile. Isn't this actually good news for SEPR since it supports the view that there is a strong incentive for Lilly to get the improved version of Prozac on the market asap? By the way, the anti-depressant market is going to grow tremendously as the boomers age.

To: David Howe who wrote (2173)	3/28/1999 8:23:00 PM
From: Ed Ajootian	Respond to of 10280

Dave, Thanks for the link. That reference to the recently-completed study is referring to the study announced 11 months ago I believe. Since then there have been two more allergy seasons completed and we are now into the third. I wonder what is up with these studies. Maybe J&J has decided to keep this drug development under tight wraps. Since J&J is paying the big bucks to co-develop it they would seem to have the say re: what gets announced and when. Wondering whether even the big pharma's such as J&J would at least announce when the NDA is filed. Maybe the SEPR 10K will have something to say about this program. As discussed at length here many moons ago Norastemizole has the potential to be the "best of class" allergy drug. The market for allergy drugs is in the billions and growing by leaps & bounds. I hope we don't have to wait until SEPR's drug pipeline chart gets updated in the '98 annual report to find out when the expected launch date is for Nori!